Mp03-02 Unveiling the Long-Term Survival Outcomes of Artificial Urinary Sphincter: A Twelve-Year Study From the French National Health Insurance Database

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Male Incontinence (MP03)1 May 2024MP03-02 UNVEILING THE LONG-TERM SURVIVAL OUTCOMES OF ARTIFICIAL URINARY SPHINCTER: A TWELVE-YEAR STUDY FROM THE FRENCH NATIONAL HEALTH INSURANCE DATABASE Louis Lenfant, Yoann Taille, Emmanuel Chartier-Kastler, Bertrand Lukaks, Aurélien Beaugerie, Eric Vicaut, and Pierre C. Mozer Louis LenfantLouis Lenfant , Yoann TailleYoann Taille , Emmanuel Chartier-KastlerEmmanuel Chartier-Kastler , Bertrand LukaksBertrand Lukaks , Aurélien BeaugerieAurélien Beaugerie , Eric VicautEric Vicaut , and Pierre C. MozerPierre C. Mozer View All Author Informationhttps://doi.org/10.1097/01.JU.0001009488.55564.85.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The artificial urinary sphincter (AUS) is the gold standard for treating severe male urinary stress incontinence, often due to radical prostate cancer (PCa) treatment or surgical procedures for benign prostatic hyperplasia (BPH). However, data on AUS revision and explantation rates are scarce. METHODS: Data regarding patients treated in France for PCa or BPH from 2006-2018 were extracted from the French national health data system and stored in the Observapur database. From this dataset, we identified patients who underwent their first AMS 800 AUS implantation, using its unique reimbursement code, as AMS is the only AUS eligible for reimbursement in France. The study aimed to evaluate reintervention-free survival following the first AUS implantation, including device revision or explantation identified by specific codes. RESULTS: Between 2006 and 2018, the Observapur database registered 5,132,311 patients, with 4,413,951 treated for BPH and 718,360 for PCa in France. In that period, there were 780,127 BPH surgeries, 266,927 radical prostatectomies, and 118,611 PCa radiation therapies. AUS implantation rates were 1.8% after radical prostatectomy and 0.28% after BPH surgery.Out of the total, 8,475 patients received their first AUS implantation between 2006 and 2018. The median age at implantation was 69 (IQR 65-74), with a median follow-up of 6 years (IQR 3-9). Of these, 68% had AUS implantation post-radical prostatectomy, 4.5% post-radiation therapy, 8.1% after both, and 19% post-BPH surgery.At the 10-year mark: 40% had not undergone reintervention, with 20% of reinterventions occurring within 10 months and a median of 6.5 years to reintervention. 67% had not undergone revision. 62% had not experienced explantation, with 12.5% of explantations happening within the first year. CONCLUSIONS: From 2006-2018 in France, 8,475 patients had AUS implantation, representing the largest AUS cohort to date with the longest follow-up. Most patients had AUS post-PCa treatment or BPH surgery. The initial post-implantation months had the highest reintervention risk. Ten years after implantation, 33% of AUS implants needed revision, 38% required explantation, and 60% needed reintervention. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e22 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Louis Lenfant More articles by this author Yoann Taille More articles by this author Emmanuel Chartier-Kastler More articles by this author Bertrand Lukaks More articles by this author Aurélien Beaugerie More articles by this author Eric Vicaut More articles by this author Pierre C. Mozer More articles by this author Expand All Advertisement PDF downloadLoading ...